As CD8 + T cells migrate to tumor sites to eliminate tumor cells [87], an increase in the number of tumor-infiltrating CD8 + T cells in the tumor microenvironment correlates with better clinical outcomes in human cancers [88–91]. The gene discussed is CD8A; the disease is cancer.